PRE-IND STUDIES OF FIRST-GENERATION DUAL-TARGETED, FINE-TUNED, IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC)

Dana-Farber Cancer Institute, Inc.

Investigators